Apothecary Pharma NAD+ and Tirzepatide Injections
Tirzepatide Injection lacks assurance of sterility.
Moderate risk
Taking it may cause temporary or medically reversible health problems. Serious harm is unlikely.
FDA Class II recall · How risk is rated
2 photos
What happened
Apothecary Pharma LLC recalled Tirzepatide Injection, 18mg/mL, 4 mL Sterile Multi-Dose Vial, and Apothecary NAD+ Injection 200 mg/mL, 6 mL Sterile Multi-Dose Vial, due to a lack of assurance of sterility. The recall began September 24, 2026, and was added to the FDA's Enforcement Report on October 8, 2026.
Summary by Recall Canary from the FDA notice.
What to do
We don't have product-specific instructions for this recall. FDA's general advice for medicine recalls:
- Check the FDA or company notice for instructions specific to this product.
- Ask your pharmacist or doctor whether your lot is affected and what to do.
Is yours affected?
2 products
Match the lot code and NDC listed under your product.
Apothecary NAD+ Injection
- Strength
- 200 mg/mL
- NDC
- 85091-011-06
- Lot
- AP-202647
Tirzepatide Injection
- Strength
- 18 mg/mL
- NDC
- 85091-001-18
- Lot
- AP-202622
Details
- Company began the recall
- Event ID
- 99952
- Company
- Apothecary Pharma LLC
- Hazard
- Sterility failure
Company began the recall
Added to FDA's Enforcement Report · Classified by FDA
Listed on Recall Canary
In FDA's weekly enforcement report
